Developments in the management of Chagas cardiomyopathy

References

• Ribeiro AL, Nunes MP, Teixeira MM, et al. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol. 2012;9(10):576–589.
   PubMed Web of Science ®Google Scholar
• Garcia MN, Aguilar D, Gorchakov R, et al. Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg. 2015;92(2):325–330.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Perez AM, Norman FF, et al. Old and new challenges in Chagas disease. Lancet Infect Dis. In press.
   Google Scholar
• Nunes MC, Dones W, Morillo CA, et al. Chagas disease: an overview of clinical and epidemiological aspects. J Am Coll Cardiol. 2013;62(9):767–776.
   PubMed Web of Science ®Google Scholar
• Tanowitz HB, Weiss LM, Montgomery SP. Chagas disease has now gone global. PLoS Negl Trop Dis. 2011;5(4):e1136.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33–44.
   PubMedGoogle Scholar
• GBD 2013 Mortality and Cause of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Silveira AC, Dias JC. The control of vectorial transmission. Rev Soc Bras Med Trop. 2011;44(Suppl 2):52–63.
   PubMed Web of Science ®Google Scholar
• Bern C, Kjos S, Yabsley MJ, et al. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev. 2011;24(4):655–681.
   PubMed Web of Science ®Google Scholar
• Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis. 2012;54(6):845–852.
   PubMed Web of Science ®Google Scholar
• Sabino EC, Ribeiro AL, Salemi VM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation. 2013;127(10):1105–1115.
   PubMed Web of Science ®Google Scholar
• Perez-Ayala A, Perez-Molina JA, Norman F, et al. Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Ann Trop Med Parasitol. 2011;105(1):25–29.
   PubMed Web of Science ®Google Scholar
• Souza DH, Vaz MD, Fonseca CR, et al. Current epidemiological profile of Chagasic megaesophagus in Central Brazil. Rev Soc Bras Med Trop. 2013;46(3):316–321.
   Web of Science ®Google Scholar
• Ribeiro AL, Sabino EC, Marcolino MS, et al. Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors. PLoS Negl Trop Dis. 2013;7(2):e2078.
   PubMed Web of Science ®Google Scholar
• Secretaria de Vigilância em Saúde do Ministério da Saúde. Consenso Brasileiro em Doença de Chagas. Rev Soc Bras Med Trop. 2005;38(Suppl 3):7–29.
   Google Scholar
• Nunes MC, Carmo AA, Rocha MO, et al. Mortality prediction in Chagas heart disease. Expert Rev Cardiovasc Ther. 2012;10(9):1173–1184.
   PubMedGoogle Scholar
• Nunes MD, Barbosa MM, Ribeiro AL, et al. Predictors of mortality in patients with dilated cardiomyopathy: relevance of Chagas disease as an etiological factor. Rev Esp Cardiol. 2010;63(7):788–797.
   PubMed Web of Science ®Google Scholar
• Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007;115(9):1101–1108.
   PubMed Web of Science ®Google Scholar
• Teixeira MM, Gazzinelli RT, Silva JS. Chemokines, inflammation and Trypanosoma cruzi infection. Trends Parasitol. 2002;18(6):262–265.
   PubMed Web of Science ®Google Scholar
• Marino AP, da Silva A, dos SP, et al. Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation. 2004;110(11):1443–1449.
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Chevillard C. Chagas disease cardiomyopathy: immunopathology and genetics. Mediators Inflamm. 2014;2014:683230.
   PubMed Web of Science ®Google Scholar
• Higuchi ML, De Morais CF, Pereira Barreto AC, et al. The role of active myocarditis in the development of heart failure in chronic Chagas’ disease: a study based on endomyocardial biopsies. Clin Cardiol. 1987;10(11):665–670.
   PubMed Web of Science ®Google Scholar
• Vazquez-Chagoyan JC, Gupta S, Garg NJ. Vaccine development against Trypanosoma cruzi and Chagas disease. Adv Parasitol. 2011;75:121–146.
   PubMed Web of Science ®Google Scholar
• Machado FS, Dutra WO, Esper L, et al. Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol. 2012;34(6):753–770.
   PubMed Web of Science ®Google Scholar
• Mariano FS, Gutierrez FR, Pavanelli WR, et al. The involvement of CD4+CD25+ T cells in the acute phase of Trypanosoma cruzi infection. Microbes Infect. 2008;10(7):825–833.
   PubMed Web of Science ®Google Scholar
• da Matta Guedes PM, Gutierrez FR, Maia FL, et al. IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis. 2010;4(2):e604.
   PubMed Web of Science ®Google Scholar
• Samudio M, Montenegro-James S, de Cabral M, et al. Differential expression of systemic cytokine profiles in Chagas’ disease is associated with endemicity of Trypanosoma cruzi infections. Acta Trop. 1998;69(2):89–97.
   PubMed Web of Science ®Google Scholar
• Moretti E, Basso B, Cervetta L, et al. Patterns of cytokines and soluble cellular receptors in the sera of children with acute Chagas’ disease. Clin Diagn Lab Immunol. 2002;9(6):1324–1327.
   PubMedGoogle Scholar
• Fonseca SG, Moins-Teisserenc H, Clave E, et al. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients. Microbes Infect. 2005;7(4):688–697.
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Kalil J. Autoimmunity in Chagas’ heart disease. Sao Paulo Med J. 1995;113(2):757–766.
   PubMedGoogle Scholar
• Nogueira LG, Santos RH, Ianni BM, et al. Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10. PLoS Negl Trop Dis. 2012;6(10):e1867.
   PubMed Web of Science ®Google Scholar
• Araujo-Jorge TC, Waghabi MC, Hasslocher-Moreno AM, et al. Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy. J Infect Dis. 2002;186(12):1823–1828.
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Dzau VJ, Allen PD, et al. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas’ disease cardiomyopathy. Am J Pathol. 2005;167(2):305–313.
   PubMed Web of Science ®Google Scholar
• Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-beta signaling in fibrosis. Growth Factors. 2011;29(5):196–202.
   PubMed Web of Science ®Google Scholar
• Araujo-Jorge TC, Waghabi MC, Bailly S, et al. The TGF-beta pathway as an emerging target for Chagas disease therapy. Clin Pharmacol Ther. 2012;95(2):613–621.
   Web of Science ®Google Scholar
• Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600–606.
   PubMed Web of Science ®Google Scholar
• Reis MM, Higuchi ML, Aiello VD, et al. Growth factors in the myocardium of patients with chronic Chagasic cardiomyopathy. Rev Soc Bras Med Trop. 2000;33(6):509–518.
   PubMedGoogle Scholar
• Saraiva RM, Waghabi MC, Vilela MF, et al. Predictive value of transforming growth factor-beta1in Chagas disease: towards a biomarker surrogate of clinical outcome. Trans R Soc Trop Med Hyg. 2013;107(8):518–525.
   PubMed Web of Science ®Google Scholar
• Pineda MA, Cuervo H, Fresno M, et al. Lack of galectin-3 prevents cardiac fibrosis and effective immune responses in a murine model of Trypanosoma cruzi infection. J Infect Dis. 2015;212(7):1160–1171.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11(9):811–817.
   PubMed Web of Science ®Google Scholar
• Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107–117.
   PubMed Web of Science ®Google Scholar
• Andrade SG, Grimaud JA, Stocker-Guerret S. Sequential changes of the connective matrix components of the myocardium (fibronectin and laminin) and evolution of cardiac fibrosis in mice infected with Trypanosoma cruzi. Am J Trop Med Hyg. 1989;40(3):252–260.
   PubMed Web of Science ®Google Scholar
• Andrade SG, Stocker-Guerret S, Pimentel AS, et al. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz. 1991;86(2):187–200.
   PubMed Web of Science ®Google Scholar
• de Oliveira FL, Araujo-Jorge TC, de Souza EM, et al. Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl Trop Dis. 2012;6(6):e1696.
   PubMed Web of Science ®Google Scholar
• Iosa D, Massari DC, Dorsey FC. Chagas’ cardioneuropathy: effect of ganglioside treatment in chronic dysautonomic patients: a randomized, double-blind, parallel, placebo-controlled study. Am Heart J. 1991;122(3 Pt 1):775–785.
   PubMed Web of Science ®Google Scholar
• Cutrullis RA, Poklepovich TJ, Postan M, et al. Immunomodulatory and anti-fibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosoma cruzi infection. Int Immunopharmacol. 2011;11(8):1024–1031.
   PubMed Web of Science ®Google Scholar
• Jelicks LA, Chandra M, Shirani J, et al. Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas’ disease. Int J Parasitol. 2002;32(12):1497–1506.
   PubMed Web of Science ®Google Scholar
• Tanowitz HB, Huang H, Jelicks LA, et al. Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun. 2005;73(4):2496–2503.
   PubMed Web of Science ®Google Scholar
• de Souza AP, Tanowitz HB, Chandra M, et al. Effects of early and late verapamil administration on the development of cardiomyopathy in experimental chronic Trypanosoma cruzi (Brazil strain) infection. Parasitol Res. 2004;92(6):496–501.
   PubMed Web of Science ®Google Scholar
• Morris SA, Weiss LM, Factor S, et al. Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol. 1989;14(3):782–789.
   PubMed Web of Science ®Google Scholar
• Johndrow C, Nelson R, Tanowitz H, et al. Trypanosoma cruzi infection results in an increase in intracellular cholesterol. Microbes Infect. 2014;16(4):337–344.
   Google Scholar
• Burleigh BA, Woolsey AM. Cell signalling and Trypanosoma cruzi invasion. Cell Microbiol. 2002;4(11):701–711.
   PubMed Web of Science ®Google Scholar
• Gupta S, Bhatia V, Wen JJ, et al. Trypanosoma cruzi infection disturbs mitochondrial membrane potential and ROS production rate in cardiomyocytes. Free Radic Biol Med. 2009;47(10):1414–1421.
   PubMed Web of Science ®Google Scholar
• Wen JJ, Garg NJ. Mitochondrial generation of reactive oxygen species is enhanced at the Q(o) site of the complex III in the myocardium of Trypanosoma cruzi-infected mice: beneficial effects of an antioxidant. J Bioenerg Biomembr. 2008;40(6):587–598.
   PubMed Web of Science ®Google Scholar
• Wen JJ, Yachelini PC, Sembaj A, et al. Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radic Biol Med. 2006;41(2):270–276.
   PubMed Web of Science ®Google Scholar
• Wen JJ, Dhiman M, Whorton EB, et al. Tissue-specific oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice. Microbes Infect. 2008;10(10–11):1201–1209.
   PubMed Web of Science ®Google Scholar
• Dhiman M, Wan X, Popov VL, et al. MnSODtg mice control myocardial inflammatory and oxidative stress and remodeling responses elicited in chronic Chagas disease. J Am Heart Assoc. 2013;2(5):e000302.
   PubMed Web of Science ®Google Scholar
• Wen JJ, Bhatia V, Popov VL, et al. Phenyl-alpha-tert-butyl nitrone reverses mitochondrial decay in acute Chagas’ disease. Am J Pathol. 2006;169(6):1953–1964.
   PubMed Web of Science ®Google Scholar
• Dhiman M, Estrada-Franco JG, Pando JM, et al. Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas’ disease. Clin Vaccine Immunol. 2009;16(5):660–666.
   PubMed Web of Science ®Google Scholar
• Ba X, Gupta S, Davidson M, et al. Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes. J Biol Chem. 2010;285(15):11596–11606.
   PubMed Web of Science ®Google Scholar
• Ba X, Garg NJ. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol. 2011;178(3):946–955.
   PubMed Web of Science ®Google Scholar
• Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Semin Immunopathol. 2015;37(3):233–238.
   PubMed Web of Science ®Google Scholar
• Garg N, Bhatia V. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines. 2005;4(6):867–880.
   PubMed Web of Science ®Google Scholar
• Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun. 2002;70(10):5547–5555.
   PubMed Web of Science ®Google Scholar
• Cazorla SI, Becker PD, Frank FM, et al. Oral vaccination with Salmonella as cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun. 2007;76(1):324–333.
   PubMed Web of Science ®Google Scholar
• Miyahira Y, Takashima Y, Kobayashi S, et al. Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun. 2005;73(11):7356–7365.
   PubMed Web of Science ®Google Scholar
• de Alencar BC, Persechini PM, Haolla FA, et al. Perforin and Interferon-γ expression are required for CD4+ and CD8+ T cell-dependent protective immunity against a human parasite (Trypanosoma cruzi) elicited by a heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun. 2009;77(10):4383–4395.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Sinha M, Luxon B, et al. Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening. Infect Immun. 2004;72(11):6245–6254.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Garg NJ. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol. 2008;15(8):1158–1164.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wan X, Zago MP, et al. Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease. PLoS Negl Trop Dis. 2013;7(1):e2018.
   PubMed Web of Science ®Google Scholar
• Aparicio-Burgos JE, Ochoa-Garcia L, Zepeda-Escobar JA, et al. Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs. PLoS Negl Trop Dis. 2011;5(5):e1050.
   PubMed Web of Science ®Google Scholar
• Gupta S, Garg NJ. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis. 2010;4(8):e797.
   PubMed Web of Science ®Google Scholar
• Gupta S, Garg NJ. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi. Vaccine. 2012;30(50):7179–7186.
   PubMed Web of Science ®Google Scholar
• Gupta S, Garg NJ. TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice. PLoS One. 2013;8(3):e59434.
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. 2005;175(2):633–639.
   PubMed Web of Science ®Google Scholar
• Bryan MA, Norris KA. Genetic immunization converts the trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen. Infect Immun. 2010;78(2):810–822.
   PubMed Web of Science ®Google Scholar
• Gupta S, Garg NJ. A two-component DNA-prime/protein-boost vaccination strategy for eliciting long-term, protective T cell immunity against Trypanosoma cruzi. PLoS Pathog. 2015;11(5):e1004828.
   PubMed Web of Science ®Google Scholar
• Cohen JE, Gurtler RE. Modeling household transmission of American trypanosomiasis. Science. 2001;293(5530):694–698.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bacon KM, Connor DL, et al. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis. 2010;4(12):e916.
   PubMed Web of Science ®Google Scholar
• Ma Y, Weiss LM, Huang H. Inducible suicide vector systems for Trypanosoma cruzi. Microbes Infect. 2015;17(6):440–450.
   PubMed Web of Science ®Google Scholar
• Pereira IR, Vilar-Pereira G, Marques V, et al. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog. 2015;11(1):e1004594.
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Vargas AP, Horan TA, et al. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke. 2005;36(5):965–970.
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010;9(5):533–542.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Barbosa MM, Ribeiro AL, et al. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J Neurol Sci. 2009;278(1–2):96–101.
   PubMed Web of Science ®Google Scholar
• Paixao LC, Ribeiro AL, Valacio RA, et al. Chagas disease: independent risk factor for stroke. Stroke. 2009;40(12):3691–3694.
   PubMed Web of Science ®Google Scholar
• Pittella JE. Central nervous system involvement in Chagas disease: a hundred-year-old history. Trans R Soc Trop Med Hyg. 2009;103(10):973–978.
   PubMed Web of Science ®Google Scholar
• Aras R, da Matta JA, Mota G, et al. Cerebral infarction in autopsies of chagasic patients with heart failure. Arq Bras Cardiol. 2003;81(4):411–413.
   PubMedGoogle Scholar
• Carod-Artal FJ. Policy implications of the changing epidemiology of chagas disease and stroke. Stroke. 2013;44(8):2356–2360.
   PubMed Web of Science ®Google Scholar
• Dias Junior JO, da Costa Rocha MO, de Souza AC, et al. Assessment of the source of ischemic cerebrovascular events in patients with Chagas disease. Int J Cardiol. 2014;176(3):1352–1354.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Barbosa MM, Rocha MO. Peculiar aspects of cardiogenic embolism in patients with Chagas’ cardiomyopathy: a transthoracic and transesophageal echocardiographic study. J Am Soc Echocardiogr. 2005;18(7):761–767.
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ, Vargas AP, Melo M, et al. American trypanosomiasis (Chagas’ disease): an unrecognised cause of stroke. J Neurol Neurosurg Psychiatry. 2003;74(4):516–518.
   PubMed Web of Science ®Google Scholar
• Espinosa RA, Pericchi LR, Carrasco HA, et al. Prognostic indicators of chronic chagasic cardiopathy. Int J Cardiol. 1991;30(2):195–202.
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Marcolino MS, Prineas RJ, et al. Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambui Cohort Study of Aging. J Am Heart Assoc. 2014;3(1):e000632.
   Web of Science ®Google Scholar
• Lima-Costa MF, Matos DL, Ribeiro AL. Chagas disease predicts 10-year stroke mortality in community-dwelling elderly: the Bambui cohort study of aging. Stroke. 2010;41(11):2477–2482.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, D’Agostino RB, Belanger AJ, et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92(4):835–841.
   PubMed Web of Science ®Google Scholar
• Ohara K, Hirai T, Fukuda N, et al. Relation of left atrial blood stasis to clinical risk factors in atrial fibrillation. Int J Cardiol. 2009;132(2):210–215.
   PubMed Web of Science ®Google Scholar
• Nunes MC, Barbosa MM, Rocha ES, et al. Function of the left atrium in Chagas’ cardiomyopathy. Arq Bras Cardiol. 2005;84(6):452–456.
   PubMedGoogle Scholar
• Carod-Artal FJ. Stroke: a neglected complication of American trypanosomiasis (Chagas’ disease). Trans R Soc Trop Med Hyg. 2007;101(11):1075–1080.
   PubMed Web of Science ®Google Scholar
• Sternick EB, Martinelli M, Sampaio R, et al. Sudden cardiac death in patients with chagas heart disease and preserved left ventricular function. J Cardiovasc Electrophysiol. 2006;17(1):113–116.
   PubMed Web of Science ®Google Scholar
• Barbosa MP, Carmo AA, Rocha MO, et al. Ventricular arrhythmias in Chagas disease. Rev Soc Bras Med Trop. 2015;48(1):4–10.
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Cavalvanti PS, Lombardi F, et al. Prognostic value of signal-averaged electrocardiogram in chagas disease. J Cardiovasc Electrophysiol. 2008;19(5):502–509.
   PubMed Web of Science ®Google Scholar
• Strauss DG, Cardoso S, Lima JA, et al. ECG scar quantification correlates with cardiac magnetic resonance scar size and prognostic factors in Chagas’ disease. Heart. 2011;97(5):357–361.
   PubMed Web of Science ®Google Scholar
• Mello RP, Szarf G, Schvartzman PR, et al. Delayed enhancement cardiac magnetic resonance Imaging can identify the risk for ventricular tachycardia in chronic Chagas’ heart disease. Arq Bras Cardiol. 2012;98(5):421–430.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Cunha-Neto E, Maciel BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109–1123.
   PubMed Web of Science ®Google Scholar
• Junqueira LF Jr. Insights into the clinical and functional significance of cardiac autonomic dysfunction in Chagas disease. Rev Soc Bras Med Trop. 2012;45(2):243–252.
   PubMed Web of Science ®Google Scholar
• Koeberle F. Cardiopathia parasympathicopriva. Münch Med Wochenschr. 1959;101:1308–1310.
   PubMedGoogle Scholar
• Amorim DS, Godoy RA, Manco JC, et al. Effects of acute elevation in blood pressure and of atropine on heart rate in Chagas’ disease. A Preliminary Report. Circulation. 1968;38(2):289–294.
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Maciel BC, Gallo JL, et al. Effect of parasympathetic impairment on the haemodynamic response to handgrip in Chagas’s heart disease. Br Heart J. 1986;55(2):204–210.
   PubMedGoogle Scholar
• Villar JC, Leon H, Morillo CA. Cardiovascular autonomic function testing in asymptomatic T. cruzi carriers: a sensitive method to identify subclinical Chagas’ disease. Int J Cardiol. 2004;93(2–3):189–195.
   PubMed Web of Science ®Google Scholar
• Guzzetti S, Iosa D, Pecis M, et al. Impaired heart rate variability in patients with chronic Chagas’ disease. Am Heart J. 1991;121(6 Pt 1):1727–1734.
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Moraes RS, Ribeiro JP, et al. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am Heart J. 2001;141(2):260–265.
   PubMed Web of Science ®Google Scholar
• Raadschilders L, Rocha MO, Sousa L, et al. Is autonomic function associated with left ventricular systolic function in Chagas heart disease patients undergoing treatment for heart failure? Rev Soc Bras Med Trop. 2014;47(2):239–242.
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Cassini P, Peixoto SV, et al. Vagal impairment in elderly Chagas disease patients: a population-based study (The Bambui Study). Int J Cardiol. 2011;147(3):359–365.
   PubMed Web of Science ®Google Scholar
• Miranda CH, Figueiredo AB, Maciel BC, et al. Sustained ventricular tachycardia is associated with regional myocardial sympathetic denervation assessed with 123I-metaiodobenzylguanidine in chronic Chagas cardiomyopathy. J Nucl Med. 2011;52(4):504–510.
   PubMed Web of Science ®Google Scholar
• Landesmann MC, da Fonseca LM, de BP, et al. Iodine-123 metaiodobenzylguanidine cardiac imaging as a method to detect early sympathetic neuronal dysfunction in chagasic patients with normal or borderline electrocardiogram and preserved ventricular function. Clin Nucl Med. 2011;36(9):757–761.
   PubMed Web of Science ®Google Scholar
• Diaz JO, Makikallio TH, Huikuri HV, et al. Heart rate dynamics before the spontaneous onset of ventricular tachyarrhythmias in Chagas’ heart disease. Am J Cardiol. 2001;87(9):1123–1125, A10.
   PubMed Web of Science ®Google Scholar
• Salles G, Xavier S, Sousa A, et al. Prognostic value of QT interval parameters for mortality risk stratification in Chagas’ disease: results of a long-term follow-up study. Circulation. 2003;108(3):305–312.
   PubMed Web of Science ®Google Scholar
• Salles GF, Xavier SS, Sousa AS, et al. T-wave axis deviation as an independent predictor of mortality in chronic Chagas’ disease. Am J Cardiol. 2004;93(9):1136–1140.
   PubMed Web of Science ®Google Scholar
• Ribeiro AL, Rocha MO, Terranova P, et al. T-wave amplitude variability and the risk of death in Chagas disease. J Cardiovasc Electrophysiol. 2011;22(7):799–805.
   PubMed Web of Science ®Google Scholar
• Sassi R, Rivolta MW, Mainardi LT, et al. Spatial repolarization heterogeneity and survival in chagas disease. Methods Inf Med. 2014;53(4):464–468.
   PubMed Web of Science ®Google Scholar
• Raadschilders L, Barbosa MP, Carmo AA, et al. Microvolt T-wave alternans in Chagas disease. Int J Cardiol. 2015;187:7–8.
   PubMed Web of Science ®Google Scholar
• Botoni FA, Poole-Wilson PA, Ribeiro AL, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007;153(4):544–548.
   PubMed Web of Science ®Google Scholar
• Roberti RR, Martinez EE, Andrade JL, et al. Chagas cardiomyopathy and captopril. Eur Heart J. 1992;13(7):966–970.
   PubMed Web of Science ®Google Scholar
• Issa VS, Amaral AF, Cruz FD, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010;3(1):82–88.
   PubMed Web of Science ®Google Scholar
• Bestetti RB, Otaviano AP, Cardinalli-Neto A, et al. Effects of B-Blockers on outcome of patients with Chagas’ cardiomyopathy with chronic heart failure. Int J Cardiol. 2011;151(2):205–208.
   PubMed Web of Science ®Google Scholar
• Muratore CA, Baranchuk A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc Health Risk Manag. 2010;6:593–601.
   PubMedGoogle Scholar
• Andrade JP, Marin Neto JA, Paola AA, et al. I Latin American Guidelines for the diagnosis and treatment of Chagas’ heart disease: executive summary. Arq Bras Cardiol. 2011;96(6):434–442.
   PubMed Web of Science ®Google Scholar
• de Sousa AS, Xavier SS, de Freitas GR, et al. Prevention strategies of cardioembolic ischemic stroke in Chagas’ disease. Arq Bras Cardiol. 2008;91(5):306–310.
   PubMedGoogle Scholar
• Fiorelli AI, Santos RH, Oliveira JL Jr, et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant Proc. 2011;43(1):220–224.
   PubMed Web of Science ®Google Scholar
• Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. Curr Opin Infect Dis. 2014;27(5):418–424.
   PubMed Web of Science ®Google Scholar
• Bestetti RB. Cardiac resynchronization therapy for patients with chronic systolic heart failure secondary to Chagas cardiomyopathy in the 21st century. Rev Bras Cir Cardiovasc. 2014;29(1):IV–VI.
   PubMed Web of Science ®Google Scholar
• Araujo EF, Chamlian EG, Peroni AP, et al. Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up. Rev Bras Cir Cardiovasc. 2014;29(1):31–36.
   PubMed Web of Science ®Google Scholar
• Cunnington C, Kwok CS, Satchithananda DK, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomised controlled trials. Heart. 2015;101(18):1456–1462.
   PubMed Web of Science ®Google Scholar
• Lima MM, Rocha MO, Nunes MC, et al. A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Eur J Heart Fail. 2010;12(8):866–873.
   PubMed Web of Science ®Google Scholar
• Sperandio da Silva GM, Chambela MC, Sousa AS, et al. Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial. Trials. 2012;13:244.
   PubMed Web of Science ®Google Scholar
• Leite CF, Almeida TR, Lopes CS, et al. Multipotent stem cells of the heart-do they have therapeutic promise? Front Physiol. 2015;6:123.
   PubMedGoogle Scholar
• Liebson PR. Stem-cell angiogenesis and regeneration of the heart: review of a saga of 2 decades. Clin Cardiol. 2015;38(5):309–316.
   PubMed Web of Science ®Google Scholar
• Leblond AL, O’Sullivan J, Caplice N. Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction. Stem Cells Cloning. 2009;2:11–19.
   PubMedGoogle Scholar
• Soares MB, Lima RS, Rocha LL, et al. Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. Am J Pathol. 2004;164(2):441–447.
   PubMed Web of Science ®Google Scholar
• Goldenberg RC, Jelicks LA, Fortes FS, et al. Bone marrow cell therapy ameliorates and reverses chagasic cardiomyopathy in a mouse model. J Infect Dis. 2008;197(4):544–547.
   PubMed Web of Science ®Google Scholar
• Soares MB, Lima RS, Souza BS, et al. Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells. Cell Cycle. 2011;10(9):1448–1455.
   PubMed Web of Science ®Google Scholar
• Soares MB, de Lima RS, Rocha LL, et al. Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy. J Infect Dis. 2010;202(3):416–426.
   PubMed Web of Science ®Google Scholar
• Alvarez-Viejo M, Menendez-Menendez Y, Blanco-Gelaz MA, et al. Quantifying mesenchymal stem cells in the mononuclear cell fraction of bone marrow samples obtained for cell therapy. Transplant Proc. 2013;45(1):434–439.
   PubMed Web of Science ®Google Scholar
• Jasmin, Jelicks LA, Koba W, et al. Mesenchymal bone marrow cell therapy in a mouse model of chagas disease. Where do the cells go? PLoS Negl Trop Dis. 2012;6(12):e1971.
   PubMed Web of Science ®Google Scholar
• Jasmin J, Jelicks LA, Tanowitz HB, et al. Molecular imaging, biodistribution and efficacy of mesenchymal bone marrow cell therapy in a mouse model of Chagas disease. Microbes Infect. 2014;16(11):923–935.
   PubMed Web of Science ®Google Scholar
• de Carvalho AC, Carvalho AB. Stem cell-based therapies in chagasic cardiomyopathy. Biomed Res Int. 2015;2015:436314.
   PubMedGoogle Scholar
• Ribeiro dos SR, Rassi S, Feitosa G, et al. Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial. Circulation. 2012;125(20):2454–2461.
   PubMed Web of Science ®Google Scholar
• Macambira SG, Vasconcelos JF, Costa CR, et al. Granulocyte colony-stimulating factor treatment in chronic Chagas disease: preservation and improvement of cardiac structure and function. FASEB J. 2009;23(11):3843–3850.
   PubMed Web of Science ®Google Scholar
• Guarita-Souza LC, Carvalho KA, Woitowicz V, et al. Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation. 2006;114(1 Suppl):I120–I124.
   PubMed Web of Science ®Google Scholar
• Shi Y, Desponts C, Do JT, et al. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3(5):568–574.
   PubMed Web of Science ®Google Scholar
• Cunha-Neto E, Teixeira PC, Nogueira LG, et al. Autoimmunity. Adv Parasitol. 2011;76:129–152.
   PubMed Web of Science ®Google Scholar
• Machado FS, Tyler KM, Brant F, et al. Pathogenesis of Chagas disease: time to move on. Front Biosci (Elite Ed). 2012;4:1743–1758.
   PubMedGoogle Scholar
• Teixeira AR, Hecht MM, Guimaro MC, et al. Pathogenesis of Chagas’ disease: parasite persistence and autoimmunity. Clin Microbiol Rev. 2011;24(3):592–630.
   PubMed Web of Science ®Google Scholar
• Bonney KM, Engman DM. Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead. Am J Pathol. 2015;185(6):1537–1547.
   PubMed Web of Science ®Google Scholar
• Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions: a comprehensive review. Mem Inst Oswaldo Cruz. 2015;110(3):277–282.
   PubMed Web of Science ®Google Scholar
• Rendell VR, Gilman RH, Valencia E, et al. Trypanosoma cruzi-infected pregnant women without vector exposure have higher parasitemia levels: implications for congenital transmission risk. PLoS One. 2015;10(3):e0119527.
   Web of Science ®Google Scholar
• Lattes R, Lasala MB. Chagas disease in the immunosuppressed patient. Clin Microbiol Infect. 2014;20(4):300–309.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas’ disease. J Infect Dis. 1999;180(2):480–486.
   PubMed Web of Science ®Google Scholar
• Schijman AG, Vigliano CA, Viotti RJ, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease. Am J Trop Med Hyg. 2004;70(2):210–220.
   PubMed Web of Science ®Google Scholar
• Benvenuti LA, Roggerio A, Freitas HF, et al. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann Trop Med Parasitol. 2008;102(6):481–487.
   PubMed Web of Science ®Google Scholar
• Sabino EC, Ribeiro AL, Lee TH, et al. Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity. Eur J Heart Fail. 2015;17(4):416–423.
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144(10):724–734.
   PubMed Web of Science ®Google Scholar
• Viotti R, Alarcon de NB, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–639.
   PubMed Web of Science ®Google Scholar
• Bern C. Chagas’ disease. N Engl J Med. 2015;373(5):456–466.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Segura EL. Integrated control of Chagas disease for its elimination as public health problem: a review. Mem Inst Oswaldo Cruz. 2015;110(3):289–298.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Perez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64(6):1139–1147.
   PubMed Web of Science ®Google Scholar
• Villar JC, Perez JG, Cortes OL, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014;5:CD003463.
   PubMedGoogle Scholar
• Marin-Neto JA, Rassi A Jr, Avezum A Jr, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;104(4):319–324.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–1306.
   PubMed Web of Science ®Google Scholar
• Molina I, Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–1908.
   PubMed Web of Science ®Google Scholar
• Carmo AA, Rocha MO, Silva JL, et al. Amiodarone and Trypanosoma cruzi parasitemia in patients with Chagas disease. Int J Cardiol. 2015;189:182–184.
   PubMed Web of Science ®Google Scholar
• Alonso-Padilla J, Rodriguez A. High throughput screening for anti-Trypanosoma cruzi drug discovery. PLoS Negl Trop Dis. 2014;8(12):e3259.
   PubMed Web of Science ®Google Scholar
• Lepesheva GI. Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Expert Opin Drug Discov. 2013;8(12):1479–1489.
   PubMed Web of Science ®Google Scholar
• Guedes PM, Oliveira FS, Gutierrez FR, et al. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas’ disease. Br J Pharmacol. 2010;160(2):270–282.
   PubMed Web of Science ®Google Scholar
• Machado FS, Tanowitz HB, Teixeira MM. New drugs for neglected infectious diseases: Chagas’ disease. Br J Pharmacol. 2010;160(2):258–259.
   PubMed Web of Science ®Google Scholar
• Sesti-Costa R, Carneiro ZA, Silva MC, et al. Ruthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas disease. PLoS Negl Trop Dis. 2014;8(10):e3207.
   PubMed Web of Science ®Google Scholar
• Nagajyothi F, Zhao D, Weiss LM, et al. Curcumin treatment provides protection against Trypanosoma cruzi infection. Parasitol Res. 2012;110(6):2491–2499.
   PubMed Web of Science ®Google Scholar
• Alvarenga Americano do Brasil PE, Pereira de SA, Hasslocher-Moreno AM, et al. Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial. Trials. 2014;15:388.
   PubMed Web of Science ®Google Scholar
• Jelicks LA, de Souza AP, Araujo-Jorge TC, et al. Would selenium supplementation aid in therapy for Chagas disease? Trends Parasitol. 2011;27(3):102–105.
   PubMed Web of Science ®Google Scholar
• Friedman AJ, Han G, Navati MS, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;19(1):12–20.
   PubMed Web of Science ®Google Scholar
• Tar M, Cabrales P, Navati M, et al. Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy. J Sex Med. 2014;11(12):2903–2914.
   PubMed Web of Science ®Google Scholar
• Cabrales P, Han G, Roche C, et al. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med. 2010;49(4):530–538.
   PubMed Web of Science ®Google Scholar
• Friedman A, Blecher K, Sanchez D, et al. Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence. 2011;2(3):217–221.
   PubMed Web of Science ®Google Scholar
• Schairer DO, Chouake JS, Nosanchuk JD, et al. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence. 2012;3(3):271–279.
   PubMed Web of Science ®Google Scholar
• Macherla C, Sanchez DA, Ahmadi MS, et al. Nitric oxide releasing nanoparticles for treatment of Candida albicans burn infections. Front Microbiol. 2012;3:193.
   PubMed Web of Science ®Google Scholar
• Nachuraju P, Friedman AJ, Friedman JM, et al. Exogenous nitric oxide prevents cardiovascular collapse during hemorrhagic shock. Resuscitation. 2011;82(5):607–613.
   PubMed Web of Science ®Google Scholar